Trials / Completed
CompletedNCT01599637
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to explore the mode of action for omalizumab therapy in patients with chronic idiopathic urticaria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IGE025 | Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial. |
| DRUG | placebo | Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-05-16
- Last updated
- 2015-03-31
- Results posted
- 2014-11-03
Locations
4 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01599637. Inclusion in this directory is not an endorsement.